Drugs / gp160 Vaccine
last change Dec 1994 re-read 2 minutes ago

gp160 Vaccine

Vaccine

Developed for
HIV infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · Protein Sciences Corporation

Trials 2 · a red edge is where a trial was stopped

1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00000745 ? → May 1991 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00001026 ? → Dec 1994 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as gp160 Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000745
1

NCT00001026

Modality Vaccine “gp160 vaccine (40 mcg)” NCT00000745